<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Twenty <z:mp ids='MP_0001261'>obese</z:mp> type 2 diabetic individuals (10 male and 10 female, aged 50 +/- 3 years, with BMI 36 +/- 2 kg/m(2) and A1C 8.3 +/- 0.6%) were studied in this single-center, placebo-controlled, randomized, double-blind study </plain></SENT>
<SENT sid="2" pm="."><plain>Five subcutaneous doses of insulin glargine (0, 0.5, 1.0, 1.5, and 2.0 units/kg) were investigated on separate occasions using the 24-h euglycemic clamp technique </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS Glargine duration of action to reduce <z:chebi fb="105" ids="17234">glucose</z:chebi>, nonessential fatty acid (NEFA), and beta-hydroxybutyrate levels was close to or &gt;24 h for <z:hpo ids='HP_0000001'>all</z:hpo> four doses </plain></SENT>
<SENT sid="4" pm="."><plain>Increases in <z:chebi fb="105" ids="17234">glucose</z:chebi> flux revealed no discernible peak and were modest with maximal <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion rates of 9.4, 6.6, 5.5, and 2.8 mumol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Glargine exhibited a relatively hepatospecific action with greater suppression (P &lt; 0.05) of endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (EGP) compared with little or no increases in <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: A single subcutaneous injection of glargine at a dose of &gt;or=0.5 units/kg can acutely reduce <z:chebi fb="105" ids="17234">glucose</z:chebi>, NEFA, and <z:chebi fb="3" ids="17087">ketone</z:chebi> body levels for 24 h in <z:mp ids='MP_0001261'>obese</z:mp> insulin-resistant type 2 diabetic individuals </plain></SENT>
<SENT sid="7" pm="."><plain>Glargine lowers blood <z:chebi fb="105" ids="17234">glucose</z:chebi> by mainly inhibiting EGP with limited effects on stimulating <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal </plain></SENT>
<SENT sid="8" pm="."><plain>Large doses of glargine have minimal effects on <z:chebi fb="105" ids="17234">glucose</z:chebi> flux and retain a relatively hepatospecific action in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>